TAGline Spring 2012
TAG at 20: Early Campaigns; The Odyssey of Therapeutic Vaccines for HIV; What You Don’t Know, You Can Sell; Does Obama’s 2013 Budget Herald the End of PEPFAR?; Childhood TB Advocacy Picks Up Steam
Children with Drug-Resistant TB Make Up the Most Neglected Patient Population
In recognition of World Tuberculosis day on March 24th, Treatment Action Group (TAG) calls for the re-focusing of attention on the tremendous burden that tuberculosis (TB) plays around the world. TB is a disease of the poor – more than 80% of TB cases worldwide arise in the global south. According to the World Health Organization, nearly 4,000 people die every day because of TB.
Being Brave: Stories of Children with Drug-Resistant Tuberculosis
March 2012 – When it comes to drug-resistant tuberculosis (DR-TB), the global community is failing to “get it right.” Millions of people around the world suffer from this dangerous, yet treatable, infectious disease. Yet, in over a decade, less than…
Childhood TB Advocacy Meeting Presentations
On January 5, 2012, TAG held a Childhood TB Federal Advocacy Meeting in Washington, D.C. The meeting was cosponsored by STOP TB, RESULTS/ACTION, the Center for Global Health Policy, and the American Thoracic Society (ATS). Some of the highlights of the…
Tallying the TB vaccines in Clinical Trials
By Richard Jefferys, with the assistance of Claire Wingfield, Eleonora Jimenez and Javid Syed. 7/1/2011 - The relatively small community of researchers, policymakers and advocates involved in the search for an effective TB vaccine met in Tallinn, Estonia in September,…
2011 TAG Update
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
US Government HIV/AIDS Clinical Trial Sites to Accelerate Completion of Phase III TB Drug Trial
TB Alliance's REMox TB program leverages ACTG sites to advance testing of improved TB treatments November 15, 2011, Durban, South Africa— The TB Alliance announces the launch of a collaboration with the National Institute of Allergy and Infectious Diseases' (NIAID)…
Treatment Action Group Issues Latest Update on Global TB R&D Investment Trends
New data released by the Treatment Action Group (TAG) and the Stop TB Partnership finds that in 2010 the world spent just $617 million in tuberculosis (TB) research and development (R&D), or 0.3% less than 2009 funding levels—the first time TAG documents no growth since it began tracking TB research investments in 2005.
2010 Report on TB Research Funding Trends
Tuberculosis Research and Development: 2010 Report on Tuberculosis Research Funding trends, 2005-2009: 2nd Edition By Eleonora Jimenez March 2011 - This is the 2nd Edition of the Stop TB Partnership and Treatment Action Group’s 2010 report on funding trends for…